Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Singulair by Quarter
Singulair (montelukast, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)
Merck Singulair: $4M in Q1 2021, down 20.0% from a year earlier. That is the lowest of the 18 quarters on record here. No newer figure appears in the documents we track.
Where the Q1 2021 figure comes from
“|| Singulair | 107 | 155 | -31 | 4 | 5 | -8 | 102 | 151 | -32”
Source: Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up singulair
Cite this data
StockData. (2026). Merck Singulair ($M), quarterly Q4 2016–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-singulair-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.